Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on July 22, 2021. The filing reports corporate governance changes effective as of the report date, specifically regarding the expansion of the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from three to four members.
- New Director: Dr. Praveen Tyle, Ph.D., was elected to fill the new vacancy, serving until the 2022 Annual Meeting.
- Committee Appointments: Dr. Tyle was appointed to the compensation, audit, and nomination and corporate governance committees.
Compensation and Equity Grants
Dr. Tyle's compensation package includes:
- Cash Compensation: $40,000 annual director fee plus $8,500 in aggregate annual committee fees.
- Stock Options: Grant of options to purchase 250,000 shares of common stock at fair market value as of July 22, 2021.
- Vesting Schedule: 10% vested immediately; the remaining 90% vests in semi-annual installments over two years, contingent on continued service.
- Change of Control: Options vest in full upon a change of control.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 250,000 new options on potential dilution.
- Confirm the fair market value per share used for the option exercise price on July 22, 2021.
- Review the Company's most recent 10-K or 10-Q for current liquidity and cash runway, as this 8-K contains no financial statements.
- Check for any subsequent filings regarding Dr. Tyle's resignation or changes to the vesting schedule.